Health Care • Medical/Dental Instruments
$5.84 ▼ -0.13
(-2.18%)
MKT CAP: $73.3M • VOL: 28.8K
52W L $5 52W H $13
LNSR // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $51.7M | $46.0M | $35.7M |
| YoY Revenue Growth % | +12.4% | +28.7% | — |
| Gross Profit | $20.3M | $18.3M | — |
| Gross Margin % | 39.4% | 39.9% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$24.6M | -$10.7M | -$12.2M |
| Operating Margin % | -47.6% | -23.2% | -34.2% |
| Net Income (GAAP) | -$34.3M | -$31.4M | -$14.4M |
| EBITDA (Normalized) | -$24.5M | -$10.5M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$14.8M | -$2.3M | -$9.7M |
| Capital Expenditures (CapEx) | $83.0K | $156.0K | — |
| Free Cash Flow (FCF) | -$14.9M | -$2.4M | -$9.7M |
| FCF Margin % | -28.9% | -5.3% | -27.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $13.0M | $16.3M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | -$26.0M | $4.9M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR LNSR.